Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15465350 | 1.00 | SLC18A3 (0.32) | SLC18A3ABL1MEN1KMT2A | |
| SCHEMBL15465141 | 0.99 | SLC18A3 (0.31) | SLC18A3ABL1MEN1KMT2A | |
| SCHEMBL15465140 | 0.99 | SLC18A3 (0.31) | SLC18A3ABL1MEN1KMT2A | |
| SCHEMBL9912468 | 0.80 | CYP1A2 (0.35) | ABL1MEN1KMT2A | |
| SCHEMBL319862 | 0.78 | ALDH1A1 (0.37) | ABL1KMT2A | |
| SCHEMBL1690922 | 0.75 | ABL1 (0.30) | ABL1 | |
| SCHEMBL9912461 | 0.75 | CYP1A2 (0.35) | KMT2A | |
| SCHEMBL17610374 | 0.73 | ATR (0.35) | ABL1MEN1KMT2A | |
| SCHEMBL9912458 | 0.71 | LMNA (0.38) | MEN1KMT2A | |
| SCHEMBL15464452 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3144300-B1 | METHODS OF PRODUCING 4-CYCLOALKYLOXYBENZENESULFONAMIDES | DAIICHI SANKYO CO LTD (JP) | 2017-12-20 | — | — | EP | disclosed |
| US-9845313-B2 | Cycloalkane derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-12-19 | — | — | US | disclosed |
| EP-3144300-A1 | METHODS OF PRODUCING 4-CYCLOALKYLOXYBENZENESULFONAMIDES | Daiichi Sankyo Company, Limited (JP) | 2017-03-22 | — | — | EP | disclosed |
| US-20170001984-A1 | CYCLOALKANE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-01-05 | — | — | US | disclosed |
| US-9493448-B2 | Cycloalkane derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-11-15 | — | — | US | disclosed |
| EP-2813491-B1 | CYCLOALKANE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2016-11-02 | — | — | EP | disclosed |
| EP-2813491-A1 | CYCLOALKANE DERIVATIVE | Daiichi Sankyo Co., Ltd. (JP) | 2014-12-17 | — | — | EP | disclosed |
| US-8889741-B2 | Cycloalkane derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-11-18 | — | — | US | disclosed |
| US-20140045862-A1 | Cycloalkane Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170001984-A1 | CYCLOALKANE DERIVATIVES | TRPV1, TRPA1, SCNN1A | SLC18A3 616/4885ABL1 3570/4885MEN1 3769/4885 |
| US-20140045862-A1 | Cycloalkane Derivatives | TRPV1, TRPA1, SCNN1A | SLC18A3 616/4885ABL1 3570/4885MEN1 3769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.